NeoGenomics said on Thursday that it has partnered with biopharmaceutical service provider Parexel to advance the application of precision medicine in clinical trials.
The partners will use real-world genomics data to accelerate patient matching and optimize trial design, site selection, clinical development, and translational research, they said in a joint statement. Specifically, they will use Boston-based Parexel’s real-world data across multiple applications including identifying and estimating the prevalence of genomic mutations within respective populations, genomic patterning to stratify patients according to novel biomarkers, and using de-identified patient data to precisely target patient populations.
The firms believe the collaboration will help researchers quickly enroll patients with common to rare cancer mutations and connect them to oncology clinical trials.
In addition, the partnership will allow biopharmaceutical customers to make evidence-based decisions regarding trial designs, companion diagnostics, and drug repurposing as well as to build external control arms using genomic data.
Fort Myers, Florida-based NeoGenomics and Parexel also are considering potential opportunities to widen the scope of the partnership to include lab services and biomarker capabilities.
“Parexel’s partnership with NeoGenomics provides access to greater predictive modeling capabilities so that we can rapidly identify specific patients and connect them to clinical trials that provide them with the best potential for treatment, advance our understanding of their disease, and identify the drug’s effects and potential benefits,” Sy Pretorius, president of clinical development and chief medical officer of Parexel, said in a statement. “This collaboration supports our efforts to adopt more novel approaches in the identification of data populations for oncology studies while keeping the patient at the center of everything we do.”
Financial details of the agreement were undisclosed.